Zymeworks to Present at Several Upcoming Investor Conferences

Zymeworks will participate in investor conferences, including Citi's Biopharma Back to School Conference, Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Annual Global Healthcare Conference, to discuss its pipeline of novel, multifunctional biotherapeutics for difficult-to-treat diseases. The company's therapeutic platforms and integrated drug development engine provide flexibility to engineer and develop highly differentiated antibody-based therapeutic candidates.

Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology company, has announced its participation in four major investor conferences in September 2025. The company, which focuses on developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases, will engage in various activities at these events. Management will attend Citi's Biopharma Back to School Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), Cantor Global Healthcare Conference (Sept 5), and Morgan Stanley Annual Global Healthcare Conference (Sept 8). The schedule includes one-on-one meetings at all events and fireside chats at three of the conferences.

Zymeworks is committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company's mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. Zymeworks has engineered and developed zanidatamab, a HER2-targeted bispecific antibody using its proprietary Azymetric™ technology. Zanidatamab has received accelerated approval from the U.S. FDA, conditional approval from the NMPA in China, and conditional marketing authorization from the European Commission for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. It is the first and only dual HER2-targeted bispecific antibody approved for this indication in the U.S., Europe, and China.

The company is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are actively recruiting, and ZW251 is expected to enter clinical trials in 2025. In addition to its pipeline, Zymeworks' therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies.

Analysts are bullish on Zymeworks, with a moderate buy consensus rating and an average price target of $20.88, implying a 69.5% upside [3]. This positive outlook reflects the company's recent financial performance and its focus on innovative biotherapeutics.

References:
[1] https://www.stocktitan.net/news/ZYME/zymeworks-announces-participation-in-upcoming-investor-w7788fc9d1d6.html
[2] https://www.globenewswire.com/news-release/2025/08/19/3135532/0/en/Zymeworks-Announces-Participation-in-Upcoming-Investor-Conferences.html
[3] https://www.ainvest.com/news/healthcare-analysts-bullish-neuren-pharmaceuticals-zymeworks-celldex-2508/